Skip to main content
OpenTrials
Completed

NCT Number: NCT00679237

Risk Reduction in Coronary Heart Disease

Study hypothesis: Multifactorial risk reduction in coronary heart disease can reduce the risk of new coronary heart disease and death

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sorlandet Hospital

Arendal, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • acute myocardial infarction, CABG or PCI

Exclusion criteria

  • Age < 18 and age > 80
  • pregnant
  • critical illness
  • drug abuse

Treatment and study plan

smoking cessation

Behavioral

NRT and varenicline

betablocker, diuretics, ACEI, ARB,

Drug

blood pressure control according to ESC guidelines

statins, ezetimibe

Drug

Cholesterol reduction according to ESC guidelines

Training

Behavioral

daily walking

influenza vaccine

Biological

vaccine (FLuarix, Influvac etc)

metformin, glimepiride, insulin

Drug

s.glucose control according to ESC guidelines

weight reduction

Behavioral

diet tips

Primary outcomes

  1. New cardiovascular events (MACE)

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Sorlandet Hospital HF

Other Gov

Collaborators

  • Oslo University Hospital

Registry information

Official study title

Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study

Acronym: SPREK!

Important dates

Study start
2007
Primary completion
2019
Study completion
2019
First posted
May 16, 2008
Registry last updated
Mar 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.